Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05457595

Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies

The study aims to obtain a local control rate in patients with lateral pelvic relapses of gynecologycal cancers previously irradiated. High LET (Linear Energy Transfer) particles as carbon ions can guarantee a biologic advantage compared to photons in radioresistant neoplasms, given to their higher biological efficacy (RBE).

Recruiting

Interested in participating?

Request Info

Key information

About this study

Primary aim: estimate the effect, in terms of clinical response, of carbon ion treatment (CIRT) in patients with lateral pelvic recurrences of gynecological malignancies.

Secondary aims:

  • To describe the safety profile of carbon ion therapy.
  • To estimate the effect, in terms of survival, of carbon ion treatment

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients ≥ 18 years of age
  • Karnofsky Index ≥ 70
  • Histological or radiological diagnosis of pelvic and groin recurrence
  • Contraindications for radical surgery
  • No other distant progression or stable disease (SD) of known secondarisms (≥6 months)
  • Previous radiation therapy on pelvis
  • Distance ≥ 10mm between tumour and close intestinal tract (small intestine), radiologically evaluated
  • Possibility to perform a surgery to space the intestinal loops, in case of distance < 10mm
  • If needed, spacer in biocompatible material (silicon, goretex) or anatomical material (omentum, muscle patch), non-absorbable.
  • DICOM (Digital Imaging and COmmunications in Medicine) images of the previous treatment plan availability
  • Written informed consent
  • Patient's ability to understand the characteristics and consequences of the clinical trial

Exclusion criteria

  • Hip prosthesis, metal prostheses or any other condition that prevents adequate imaging to identify the target volume and calculate the dose in the treatment plan
  • Intestinal infiltration
  • Bladder infiltration
  • Vessel infiltration
  • Previous therapy with anti-angiogenesis drugs
  • Psychic or other disorders that may prevent informed consent
  • Previous invasive tumor, with the exception of skin cancer (excluding melanoma) unless disease-free for at least 3 years
  • Spacer in absorbable material (i.e. vycril)
  • Distance < 10mm between tumour and close intestinal tract (small intestine), radiologically evaluated
  • Impossibility to assess MRI

Treatment and study plan

carbon ion radiation therapy

Radiation

CIRT: Planning Target Volume (PTV) will be delivered a total dose of 48-52.8 GyRBE in 12 fractions, 4 fractions per week. Treatment duration 3 weeks.

Treatment lasting more than 5 weeks or cases of treatment with less than 6 fractions in 14 consecutive days will not be accepted.

Other names: CIRT

Primary outcomes

  1. local control

    Time frame: 1 year after treatment

    absence of progression disease, in patients with lateral pelvic recurrences of gynecological malignancies

  2. complete response

    Time frame: 1 year after treatment

    complete regression of the tumor lesion

  3. partial response

    Time frame: 1 year after treatment

    Reduction of the tumor volume > 65% of the initial volume

  4. stable disease

    Time frame: 1 year after treatment

    Volume between PR and PD

  5. progression disease

    Time frame: 1 year after treatment

    Volume increase > 73% of the initial volume.

Secondary outcomes

  1. overall survival

    Time frame: 1 year after treatment

    overall survival

  2. Toxicity assessment according to CTCAE v. 5

    Time frame: 1 year after treatment

    Tto define acute, intermediate and late toxicities according to Common Terminology Criteria for Adverse Events (CTCAE version 5.0)

  3. Progression free survival

    Time frame: 1 year after treatment

    Progression free survival (PFS) with qualitative evaluation as a narrative of progression

Study contacts

Contact information is provided by the study sponsor or research team.

Amelia Barcellini, MD

CONTACT

[email protected]

390382075501

Cristina Bono, MSc

CONTACT

[email protected]

390382075613

Sponsors and collaborators

Lead sponsor

CNAO National Center of Oncological Hadrontherapy

Other

Registry information

Official study title

Phase II Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies

Acronym: CYCLOPS

Important dates

Study start
2021
Primary completion
2028
Study completion
2028
First posted
Jul 14, 2022
Registry last updated
Aug 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.